Matt joined The Scripps Research Institute (TSRI) in November 2016 as Vice President, Business Development, responsible for leading the newly formed joint business development function with California Institute for Biomedical Research (Calibr), a TSRI affiliate institute focused on drug discovery. Matt is also Chief Operating Officer and Secretary to the Board of Directors at Calibr, where he is responsible for the day to day operation of the institute, as well as external relationships with academic, foundation and commercial partners, and works closely with the CEO to develop corporate strategy and advance new business development opportunities. Matt facilitated the launch of a number of strategic initiatives at Calibr, including drug discovery collaborations with the Juvenile Diabetes Research Foundation, the Bill & Melinda Gates Foundation, Bristol-Myers Squibb, and Pfizer. He was involved with research at Calibr since its inception in April 2012, leading a team of biologists in the discovery of new therapeutic agents for metabolic, cardiovascular, and autoimmune diseases. Before joining Calibr, Matt led a group at the Genomics Institute of the Novartis Research Foundation (GNF) in drug discovery for type 1 diabetes. Matt earned his Ph.D. in chemistry from Columbia University in 2007 before spending two years as a postdoctoral fellow in Peter Schultz’s lab at The Scripps Research Institute.